Emicizumab prophylaxis vs immune tolerance induction in children with severe hemophilia A and inhibitors: a retrospective comparison of bleeding control, quality of life, and cost

Background: There is limited evidence directly comparing emicizumab (EMI) prophylaxis and immune tolerance induction (ITI) in children with severe hemophilia A and high-titer inhibitors (SHAcwHTI), particularly bleeding control, quality of life (QoL), and cost. Objectives: This study compared outcom...

Повний опис

Бібліографічні деталі

Автори:	Zhengping Li, Qianqian Mao, Gang Li, Xiaoling Cheng, Yingzi Zhen, Guoqing Liu, Wanru Yao, Zekun Li, Jialu Zhang, Shuyue Dong, Di Ai, Zhenping Chen, Runhui Wu
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Elsevier 2026-03-01
Серія:	Research and Practice in Thrombosis and Haemostasis
Предмети:	Children emicizumab immune tolerance induction inhibitors severe hemophilia A
Онлайн доступ:	http://www.sciencedirect.com/science/article/pii/S247503792600083X
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!